1. Home
  2. APYX vs BMEA Comparison

APYX vs BMEA Comparison

Compare APYX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APYX
  • BMEA
  • Stock Information
  • Founded
  • APYX 1982
  • BMEA 2017
  • Country
  • APYX United States
  • BMEA United States
  • Employees
  • APYX N/A
  • BMEA N/A
  • Industry
  • APYX Medical/Dental Instruments
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • APYX Health Care
  • BMEA Health Care
  • Exchange
  • APYX Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • APYX 66.5M
  • BMEA 65.8M
  • IPO Year
  • APYX 1987
  • BMEA 2021
  • Fundamental
  • Price
  • APYX $1.99
  • BMEA $1.81
  • Analyst Decision
  • APYX Hold
  • BMEA Strong Buy
  • Analyst Count
  • APYX 2
  • BMEA 10
  • Target Price
  • APYX N/A
  • BMEA $22.30
  • AVG Volume (30 Days)
  • APYX 64.5K
  • BMEA 5.2M
  • Earning Date
  • APYX 08-07-2025
  • BMEA 07-30-2025
  • Dividend Yield
  • APYX N/A
  • BMEA N/A
  • EPS Growth
  • APYX N/A
  • BMEA N/A
  • EPS
  • APYX N/A
  • BMEA N/A
  • Revenue
  • APYX $47,288,000.00
  • BMEA N/A
  • Revenue This Year
  • APYX $2.25
  • BMEA N/A
  • Revenue Next Year
  • APYX $6.76
  • BMEA N/A
  • P/E Ratio
  • APYX N/A
  • BMEA N/A
  • Revenue Growth
  • APYX N/A
  • BMEA N/A
  • 52 Week Low
  • APYX $0.76
  • BMEA $1.29
  • 52 Week High
  • APYX $2.06
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • APYX 62.71
  • BMEA 44.35
  • Support Level
  • APYX $1.70
  • BMEA $2.24
  • Resistance Level
  • APYX $2.06
  • BMEA $3.08
  • Average True Range (ATR)
  • APYX 0.17
  • BMEA 0.40
  • MACD
  • APYX -0.01
  • BMEA -0.03
  • Stochastic Oscillator
  • APYX 70.72
  • BMEA 25.07

About APYX Apyx Medical Corporation

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: